+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Equine Encephalitis - Pipeline Insight, 2021

  • ID: 5448100
  • Drug Pipelines
  • September 2021
  • Region: Global
  • 60 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • AlphaVax
  • Bavarian Nordic
  • Mapp Biopharmaceutical
  • Merck & Co
  • Ridgeback Biotherapeutics
This “Equine encephalitis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Equine encephalitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage
Equine encephalitis Understanding

Equine encephalitis: Overview


Western, Eastern and Venezuelan equine encephalitis viruses vary in infection rates and severity of disease, although all three pathogens are associated with risks of flu-like symptoms, potential central nervous disorders, and death. The virus is spread by mosquitos to humans and can result in the rare condition of encephalitis in about 5% of the people that become infected. In the United States, an increase in cases of Eastern equine encephalitis, known also as Triple E, has been reported over the past years, and in 2019 almost 40 cases, including 15 deaths were reported by the CDC in what is the largest ever recorded outbreak of Triple E. There are currently no approved vaccines against any of the equine encephalitis viruses.

"Equine encephalitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Equine encephalitis pipeline landscape is provided which includes the disease overview and Equine encephalitis treatment guidelines. The assessment part of the report embraces, in depth Equine encephalitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Equine encephalitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Equine encephalitis R&D. The therapies under development are focused on novel approaches to treat/improve Equine encephalitis.

Equine encephalitis Emerging Drugs Chapters


This segment of the Equine encephalitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Equine encephalitis Emerging Drugs


MVA-BN® WEV: Bavarian Nordic


Under a contract with the U.S. Government, awarded in 2018, Bavarian Nordic has developed MVA-BN WEV, a vaccine against equine encephalitis virus, an emerging mosquito-borne virus which can result in the rare condition of encephalitis and death. In June 2020, topline results from the first-in-human trial of MVA-BN WEV were reported. Data from the study showed that the vaccine was well tolerated and immunogenic across all dose groups. Neutralizing antibody responses were observed in all dose groups, with peak levels reached after the second vaccination. These clinically meaningful Phase 1 data warrant further clinical investigation, and Bavarian Nordic is seeking additional funding for the further clinical advancement of the vaccine candidate.

Molnupiravir: Ridgeback Biotherapeutics/Merck


Molnupiravir is a direct-acting oral, broad-spectrum antiviral agent in clinical development as a treatment for COVID-19. Ridgeback has completed Phase 1 and Phase 2 studies. The program has advanced into Phase 3 development as a therapeutic for COVID-19. Administered as an oral capsule, Molnupiravir has also shown activity in animal models of Ebola, Equine Encephalitis (VEEV and EEEV), Influenza (seasonal, pandemic and avian), and Respiratory Syncytial Virus. Molnupiravir is being developed under a collaboration agreement with Merck (known as MSD outside the U.S. and Canada).

Equine encephalitis: Therapeutic Assessment


This segment of the report provides insights about the different Equine encephalitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Equine encephalitis


There are approx. 3+ key companies which are developing the therapies for Equine encephalitis. The companies which have their Equine encephalitis drug candidates in the most advanced stage, i.e. phase I include, Bavarian Nordic.

Phases


This report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Equine encephalitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Equine encephalitis: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Equine encephalitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Equine encephalitis drugs.

Equine encephalitis Report Insights

  • Equine encephalitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Equine encephalitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Equine encephalitis drugs?
  • How many Equine encephalitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Equine encephalitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Equine encephalitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Equine encephalitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Bavarian Nordic
  • Merck & Co
  • Ridgeback Biotherapeutics
  • AlphaVax
  • Mapp Biopharmaceutical

Key Products

  • Molnupiravir
  • MVA-BN® WEV

Research programme: biodefence vaccines


Rresearch programme: Venezuelan equine encephalomyelitis anti-infective antibodies

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AlphaVax
  • Bavarian Nordic
  • Mapp Biopharmaceutical
  • Merck & Co
  • Ridgeback Biotherapeutics
Introduction

Executive Summary

Equine encephalitis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Equine encephalitis - Analytical Perspective

Early Stage Products (Phase I)
  • Comparative Analysis
MVA-BN® WEV: Bavarian Nordic
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Molnupiravir: Merck & Co/Ridgeback Biotherapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Equine encephalitis Key Companies

Equine encephalitis Key Products

Equine encephalitis- Unmet Needs

Equine encephalitis- Market Drivers and Barriers

Equine encephalitis- Future Perspectives and Conclusion

Equine encephalitis Analyst Views

Equine encephalitis Key Companies

Appendix

List of Tables
Table 1 Total Products for Equine encephalitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Equine encephalitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bavarian Nordic
  • Merck & Co
  • Ridgeback Biotherapeutics
  • AlphaVax
  • Mapp Biopharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll